Optimax Holdings Berhad

KLSE:OPTIMAX Stock Report

Market Cap: RM 347.7m

Optimax Holdings Berhad Valuation

Is OPTIMAX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of OPTIMAX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: OPTIMAX (MYR0.64) is trading below our estimate of fair value (MYR1.36)

Significantly Below Fair Value: OPTIMAX is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OPTIMAX?

Key metric: As OPTIMAX is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for OPTIMAX. This is calculated by dividing OPTIMAX's market cap by their current earnings.
What is OPTIMAX's PE Ratio?
PE Ratio27.2x
EarningsRM 12.80m
Market CapRM 347.71m

Price to Earnings Ratio vs Peers

How does OPTIMAX's PE Ratio compare to its peers?

The above table shows the PE ratio for OPTIMAX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average25.4x
METRO Metro Healthcare Berhad
28.3xn/aRM 185.0m
TMCLIFE TMC Life Sciences Berhad
31.2xn/aRM 888.4m
ALPHA Alpha IVF Group Berhad
31.1x17.9%RM 1.7b
FOCUSP Focus Point Holdings Berhad
10.9x10.9%RM 374.2m
OPTIMAX Optimax Holdings Berhad
27.2x16.9%RM 347.7m

Price-To-Earnings vs Peers: OPTIMAX is expensive based on its Price-To-Earnings Ratio (27.2x) compared to the peer average (25.4x).

Price to Earnings Ratio vs Industry

How does OPTIMAX's PE Ratio compare vs other companies in the Asian Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
OPTIMAX 27.2xIndustry Avg. 21.1xNo. of Companies49PE01632486480+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: OPTIMAX is expensive based on its Price-To-Earnings Ratio (27.2x) compared to the Asian Healthcare industry average (20.8x).

Price to Earnings Ratio vs Fair Ratio

What is OPTIMAX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OPTIMAX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio27.2x
Fair PE Ratio21.6x

Price-To-Earnings vs Fair Ratio: OPTIMAX is expensive based on its Price-To-Earnings Ratio (27.2x) compared to the estimated Fair Price-To-Earnings Ratio (21.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst OPTIMAX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentRM 0.64
RM 0.83
+30.1%
5.4%RM 0.87RM 0.76n/a4
Nov ’25RM 0.66
RM 0.83
+26.1%
5.4%RM 0.87RM 0.76n/a4
Oct ’25RM 0.67
RM 0.83
+24.3%
5.4%RM 0.87RM 0.76n/a4
Sep ’25RM 0.66
RM 0.83
+27.1%
5.4%RM 0.87RM 0.76n/a4
Aug ’25RM 0.71
RM 0.82
+15.8%
7.5%RM 0.87RM 0.72n/a4
Jul ’25RM 0.69
RM 0.81
+19.0%
7.0%RM 0.87RM 0.72n/a4
Jun ’25RM 0.68
RM 0.81
+20.0%
8.0%RM 0.87RM 0.72n/a3
May ’25RM 0.65
RM 0.85
+31.8%
1.2%RM 0.86RM 0.84n/a2
Apr ’25RM 0.69
RM 0.85
+22.3%
1.2%RM 0.86RM 0.84n/a2
Mar ’25RM 0.60
RM 0.85
+41.7%
1.2%RM 0.86RM 0.84n/a2
Feb ’25RM 0.60
RM 0.85
+41.7%
1.2%RM 0.86RM 0.84n/a2
Jan ’25RM 0.63
RM 0.85
+36.0%
1.2%RM 0.86RM 0.84n/a2
Dec ’24RM 0.63
RM 0.98
+57.6%
12.7%RM 1.11RM 0.86n/a2
Nov ’24RM 0.67
RM 0.98
+48.1%
12.7%RM 1.11RM 0.86RM 0.662
Oct ’24RM 0.68
RM 0.98
+44.9%
12.7%RM 1.11RM 0.86RM 0.672
Sep ’24RM 0.70
RM 0.98
+39.7%
12.7%RM 1.11RM 0.86RM 0.662
Aug ’24RM 0.71
RM 1.04
+45.5%
12.3%RM 1.15RM 0.86RM 0.713
Jul ’24RM 0.72
RM 1.04
+43.4%
12.3%RM 1.15RM 0.86RM 0.693
Jun ’24RM 0.71
RM 1.04
+45.5%
12.3%RM 1.15RM 0.86RM 0.683
May ’24RM 0.71
RM 1.04
+45.5%
12.3%RM 1.15RM 0.86RM 0.653
Apr ’24RM 0.73
RM 1.04
+41.5%
12.3%RM 1.15RM 0.86RM 0.693
Mar ’24RM 0.76
RM 1.04
+37.7%
12.3%RM 1.15RM 0.86RM 0.603
Feb ’24RM 0.79
RM 1.00
+27.4%
11.8%RM 1.12RM 0.84RM 0.603
Jan ’24RM 0.79
RM 0.97
+23.6%
11.8%RM 1.12RM 0.84RM 0.634
Dec ’23RM 0.78
RM 0.97
+24.4%
11.8%RM 1.12RM 0.84RM 0.634
Nov ’23RM 0.76
RM 0.87
+15.6%
12.5%RM 1.04RM 0.74RM 0.674

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies